along with electromyographic findings. All the patients died during the course of observation. The cases were (A) 41 patients with amyotrophic lateral sclerosis (ALS), (B) 5 patients with spinal progressive muscular atrophy (SPMA), (C) 6 patients with progressive bulbar palsy (PBP).
Familial spastic paraplegia, HTLV-1 associated myelopathy (Osame et al. 1986 ), Kugelberg-Welander disease, hereditary neurogenic proximal muscular atrophy, and Charcot-Marie-Tooth disease were excluded from the present study. Methods. Immunoglobulins in the CSF and serum were measured by the single radial immunodiffusion method.
The concentrated CSF was used for the measurement of IgA, IgM and Kappa/Lambda (K/L) ratio. Data were analyzed by Welch's t-test, and p values less than 0.05 were taken as criteria of significant differences in mean values. Values are given in terms of means ± S.D.
RESULTS
Statistical analysis in relation to the type of disease Age of onset. The age of onset ranged from 22 to 66 years old ( Table 1 ). The mean age ± s.D. at the onset of ALS was 49.8± 11.8 years. The age of onset was 46.0+4.1 years in SPMA and 56.7+7.9 years in PBP ( Table 2) .
Sex Ratio. Two and a half times as many males as females were affected with this disease. The male to female ratio was 2.4 in ALS, 4.0 in SPMA and 1.5 in PBP, and the overall ratio for MND was 2.5 (Table 1) .
Duration of illness. The period from the onset of clinical signs to death was 35.5±17.5 months in ALS, 90.2±19.9 months in SPMA, and 33.2±15.5 in PB P (Table 2) . Thus the survival period of each type listed in increasing order as PBP < ALS < SPMA.
Statistical analysis in relation to the site of initial signs
In each type of disease, correlation between the site of initial signs (and symptoms) and the course of illness was analyzed (Table 3) .
ALAS. The disease first developed in the upper limbs in 31 cases (75.6%) and SPMA. The disease first developed in the upper limbs in two cases and in the lower limbs in three cases, and the age of onset was 43.5± 4.9 years and 47.7± 3.2 years, respectively. The period from the onset of illness to the appearance of bulbar signs was 48.0+7.1 months and 75.3+34.1 months for the upper and lower limb groups, respectively. The period from the appearance of bulbar signs to death was 28.5 + 12.0 months and 24.0 + 27.8 months, respectively. The period for Table 4 and Fig. 1 Pleocytosis was observed in three patients with ALS, and in one case of PBP. Out of 52 cases only three showed positive serum rheumatoid factor (RF), and pleocytosis was observed in two of them.
The total protein levels were elevated in five patients with ALS (12%), all males, and the course of illness in these cases was shorter (from 24 to 39 months). In all five cases, specimens were obtained after the appearance of bulbar signs. On the other hand, an increase of protein was observed in one of five patients with SPMA. This specimen was obtained before the appearance of bulbar signs.
Increased levels of CSF IgG% were seen in nine patients (22%) with ALS, two cases of which also showed abnormally high values of IgA%. However, none CSF findings in 52 cases with motor neuron disease of the nine patients had an abnormal K/L ratio. The two above mentioned ALS cases with high levels of IgA% showed abnormally high IgG%. Three patients with PBP (50%) also had abnormally high IgA% levels.
An abnormal K/L ratio was observed in three patients (7.3%) with ALS, one patient (16.7%) with PBP, and three patients (60%) with SPMA. Among these three SPMA cases, one showed an increased protein value and the other, a victim of the Hiroshima atomic bomb, exhibited increased CSF protein and abnormal serum immunoglobulin.
Among our MND cases (Table 5) , the increase of CSF IgG% was observed in 50% of the lower limb group of ALS and 33% of the lower limb group of SMPA. The IgA% levels increased in 50% of the PBP patients and 20% of the lower limb group of ALS patients. An abnormal K/L ratio was observed in 60% of SPMA and 16.7% of PBP. Serum immuno globulin levels ALS. Four cases showed an increase in serum IgG levels ; one case of which also showed an increase in the protein content in the CSF and another case showed an increase of the CSF IgG.
Four cases showed low IgM levels. One of them showed an increase of the CSF protein and another one showed an increased IgG% value in the CSF. Five cases had an abnormal K/L ratio ; four of which were K-type and one was L-type, but none of them showed an abnormal K/L ratio in the CSF. Thus, there seemed to be no direct relationship between abnormalities of immunoglobulins in the CSF and in the serum. SPMA. Abnormal serum immunoglobulin levels were observed in two cases (Table 6) . One of them, the atomic bomb victim, showed high IgG levels, low IgM levels, and an abnormal K/L ratio (K-type). In addition, he exhibited an abnormal K/L ratio of the CSF (K-type). PBP. Two patients with PBP showed abnormally low serum IgM levels (38 and 39 mg/ 100 ml). Tsubaki (1979) , Kuroiwa et al. (1979) , and Sobue et al. (1980) described the clinical courses of MND in Japan, but a few reports Guiloff et al. 1980 ) have discussed CSF findings in relation to their types of disease and courses of illness. In this report, the site of initial signs, progression of disease and duration of illness of 52 patients with MND were studied correlatively with immunoglobulin levels in CSF and serum.
DISCUSSION
Age at onset. The age at onset of all types of MND ranged from 22 to 66 years. The mean age of onset in ALS was 49.8 years. These results agree well with previous reports (Nagano et al. 1977; Kuroiwa et al. 1979; Tsubaki 1979 ). Next we studied the age of onset in relation to the site of onset. In ALS patients with initial signs in the upper limbs, the age at onset was 48.7+ 12.6 years. The ages of 47.2 and 49.5 years were reported, respectively, by Boman and Meurman (1967) and Nagano et al. (1977) . On the other hand, in the lower limb group the age at onset was 53.2 + 8.7 years. This result agrees well with the report by Boman and Meurman (1967) , but differs noticeably from the report by Nagano et al. (1977) . Patients who initially developed bulbar palsy had a higher age at onset (56.7 + 7.9) than the other ALS patients, which agrees well with other reports (Nishigaki et al. 1964 ; Boman and Meurman 1967; Nagano et al. 1977) . The age of onset in SPMA patients was relatively younger (46.0+4.1 years). Sex ratio. In our cases, the male/female ratio among the ALS patients was 2.4: 1, while previous reports described the ratios ranging from 1.1:1 to 3.3: 1 (Collins 1903; Nishigaki et al. 1964; Nagano et al. 1977; Kuroiwa et al. 1979; Sobue et al. 1980) . All reports are consistent in a predominance of males in MND (Bonduelle 1975) . The male/female ratio in our SPMA patients was 4.0: 1. The overall ratio reported in Japan was 4.4: 1 (Tsubaki 1979) , while Kuroiwa et al. (1979) reported a ratio of 2.4: 1.
Site of initial signs and symptoms. The upper limbs were the site of initial signs and symptoms in 75.6% of our ALS cases. This agrees with other reports (Nagano et al. 1977; Kuroiwa et al. 1979; Tsubaki 1979; Sobue et al. 1980) , suggesting a higher incidence of the involvement of the upper limbs.
PBP was observed in 6 patients (11.5%). PBP cases were reported to comprise 21.5% of the total MND by Tsubaki (1979) , 25.7% by Nagano et al. (1977) and 34% by Kuroiwa et al. (1979) .
Duration of illness. In our cases the average duration of illness was 35.5 + 17.5 months in ALS. This result agrees well with reports by Bonduelle (1975) (35.4 months), Sobue et al. (1980) (31 months), and Kondo (1970) (32 months). Sobue et al. (1980) reported that the duration of illness was from one to three years in 60% of the ALS patients, and that only 6% of the patients survived for more than five years.
Next we studied the correlation between the site of onset and the duration of illness (Table 3 ). In ALS, the duration of illness of the upper limb group (33.6+ 15.6 months) was shorter than in the lower limb group (41.2+22.2 months). This tendency was observed also in SPMA. Similar results were reported by Wechsler et al. (1944) and Friedman and Freedman (1950) . However, Hirayama (1959) and Sobue et al. (1980) reported that the duration of illness of the upper limb group was longer than that of the lower limb group. In the PBP type, the duration of illness was the shortest (33.2+ 15.5 months). This result confirmed others (Wechsler et al. 1944; Friedman and Freedman 1950; Bonduelle 1975; Sobue et al. 1980) . The duration from the onset of bulbar signs to death in ALS (19 months) appeared shorter than the duration of illness in PBP.
CSF findings. There are many previous reports about CSF findings of MND patients, and a 17% to 39% increase in CSF protein has been observed (Cumings 1962; Castaigne et al. 1971; Takase 1974; Ohara et al. 1977 ; Guiloff et al. 1980) . In our cases an increase of protein was observed in 12.2% of ALS and 20% of SPMA (Table 4 ). It was reported that an increase of IgG was observed in 20 to 30% of the cases (Castaigne et al. 1971; Takase et al. 1973 ; Kjellin and Stibler 1976) . Among our MND cases, the increase of CSF IgG% was observed in 22% of ALS and an abnormally high IgG% level was observed in 50% of the lower limb group of ALS patients and 33% of the lower limb group of SPMA patients. The IgA% levels increased in 50% of the PBP patients. An abnormal K/L ratio was observed in 60% of SPMA and 16.7% of PBP. Therefore our findings suggest that the abnormalities of CSF immunoglobulin in MND might be correlated with the site of onset and the type of disease. 
